Article
Medicine, General & Internal
Jingsheng Cai, Fan Yang, Xun Wang
Summary: This study aims to investigate occult non-small cell lung cancer (NSCLC), an underappreciated tumor, and found that it is an aggressive tumor with poor prognosis. Surgery is the preferred treatment. More attention should be paid to this overlooked disease due to no evidence of tumor imaging.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Shawn J. Rice, Chandra P. Belani
Summary: Blood-based biomarkers, including systemic inflammation indicators and circulating factors, are associated with poor prognosis in lung cancer patients. Elevated levels of inflammation markers were found in non-small cell lung cancer (NSCLC) patients compared to small cell lung cancer (SCLC) and disease-free (DF) patients. Specific markers were identified as predictors of progression and overall survival in NSCLC patients, highlighting the potential for personalized treatment strategies.
Article
Oncology
Hailiang Ran, Jie Ma, Le Cai, Hai Zhou, Zhongqin Yuan, Ying Chen, Wei Chang, Yunchao Huang, Yuanyuan Xiao
Summary: This study found a significant association between serum cholinesterase (ChE) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients, with higher levels of ChE being related to better prognosis. Subgroup analysis revealed that the association between ChE levels and survival in NSCLC patients was more pronounced in specific circumstances.
Article
Multidisciplinary Sciences
Ming-Hung Chang, Kuo-Hwa Chiang, Jiunn-Min Shieh, Kuo-Chen Cheng, Chung-Han Ho
Summary: Miliary lung metastasis is not a dominant indicator for outcome evaluation in patients with non-small cell lung cancer harboring EGFR mutation under TKI prescription. Other strong prognostic indicators include performance status, liver metastasis, EGFR type, and generation of TKI.
SCIENTIFIC REPORTS
(2022)
Article
Pharmacology & Pharmacy
Balazs Gyorffy
Summary: This study established a comprehensive database of transcriptome-level data for lung cancer, which can be used to identify and rank the most promising biomarkers and therapeutic targets for different subtypes of lung cancer.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Article
Oncology
Xiaotong Qiu, Yong Wang, Fen Liu, Lihong Peng, Chen Fang, Xiaoyin Qian, Xinwei Zhang, Qian Wang, Zhehao Xiao, Renfang Chen, Shangkun Yuan, Yong Li
Summary: Studies have shown that non-small cell lung cancer patients with EGFR mutations, but with concurrent PIK3CA mutations, treated with EGFR-TKIs have a shorter time to progression and lower overall survival rates.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Radiology, Nuclear Medicine & Medical Imaging
Hsiu-Ping Chou, Kuan-Hsun Lin, Hsu-Kai Huang, Li-Fan Lin, Ying-Yi Chen, Ti-Hui Wu, Shih-Chun Lee, Hung Chang, Tsai-Wang Huang
Summary: SUVmax was identified as a prognostic factor for resected stage IA NSCLC, providing potential clinical significance. Postoperative treatment may be considered for stage IA3 NSCLC with SUVmax > 4.
EUROPEAN RADIOLOGY
(2021)
Article
Multidisciplinary Sciences
Ze Yang, Jihang Luo, Mengmei Zhang, Meixiao Zhan, Yuju Bai, Yi Yang, Wei Wang, Ligong Lu
Summary: This study found a correlation between the expression of the TMSB4X gene and poorer disease-free survival (DFS) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients. It suggests that TMSB4X may modulate the tumor immune microenvironment by influencing dendritic cell function, thus facilitating tumor immune escape.
Article
Cell Biology
Hao Huang, Ding Zhang, Jinming Fu, Liyuan Zhao, Dapeng Li, Hongru Sun, Xinyan Liu, Jing Xu, Tian Tian, Lei Zhang, Ying Liu, Yuanyuan Zhang, Yashuang Zhao
Summary: The study found that high TSKU expression is associated with poor prognosis in NSCLC patients, especially when B cell infiltration is low. Additionally, the proportion of B cells with TSKU hypermethylation was higher in NSCLC patients.
Article
Biochemistry & Molecular Biology
Cheng-Gong Liao, Xiao-Hua Liang, Yuan Ke, Li Yao, Man Liu, Ze-Kun Liu, Lin He, Yi-Xiao Guo, Huijie Bian, Zhi-Nan Chen, Ling-Min Kong
Summary: This study reveals that active demethylation of CD147 is involved in the metastasis of non-small cell lung cancer (NSCLC), and targeted methylation of CD147 can inhibit the invasion and metastasis of NSCLC, providing a promising therapeutic target for NSCLC.
Article
Biotechnology & Applied Microbiology
Juanjuan Yong, Liyun Huang, Gengbiao Chen, Xiaoya Luo, Hui Chen, Lin Wang
Summary: Stabilin-2 is found to regulate cancer progression, with higher expression indicating poor prognosis in NSCLC patients. The expression of Stabilin-2 is associated with N stage and age, and it is a significant predictor for overall survival (OS) and disease-free survival (DFS) in NSCLC.
Article
Oncology
Xiao-Yue Liu, Xi Zhang, Qi Zhang, Guo-Tian Ruan, Tong Liu, Hai-Lun Xie, Yi-Zhong Ge, Meng-Meng Song, Li Deng, Han-Ping Shi
Summary: This study investigated the predictive ability of the C-reactive protein-albumin-lymphocyte (CALLY) index for the prognosis of non-small cell lung cancer (NSCLC) patients and developed a corresponding prognostic model. The results showed that the CALLY index is a valuable biomarker for evaluating the prognosis of lung cancer patients, and the prognostic model based on the CALLY index has a highly effective prediction of overall survival (OS) in NSCLC patients.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Andrea Ambrosini-Spaltro, Claudia Rengucci, Laura Capelli, Elisa Chiadini, Daniele Calistri, Chiara Bennati, Paola Cravero, Francesco Limarzi, Sofia Nosseir, Riccardo Panzacchi, Mirca Valli, Paola Ulivi, Giulio Rossi
Summary: This study analyzed the clinicopathological features of lung carcinomas with BRAF mutations, finding that patients with V600E mutations had a better prognosis, while co-mutations did not affect prognosis.
Article
Multidisciplinary Sciences
Ruhan Zhao, Yunnan Dai, Xinyang Li, Cuimin Zhu
Summary: By retrospectively analyzing patients with lung cancer combined with liver metastases, multiple independent prognostic factors were identified. A personalized prognostic nomogram was established and validated, providing guidance for the development of patient treatment plans.
SCIENTIFIC REPORTS
(2022)
Article
Biochemistry & Molecular Biology
Yingsheng Wen, Guangran Guo, Longjun Yang, Lianjuan Chen, Dechang Zhao, Xiaotian He, Rusi Zhang, Zirui Huang, Gongming Wang, Lanjun Zhang
Summary: This study identified a potentially effective model for estimating overall survival in lung cancer patients by analyzing the tumor microenvironment (TME) components. A gene panel consisting of seven TME-related genes was proposed as a candidate signature set. The study also revealed that patients at high-risk had less immune cells infiltration and more fibroblasts in their tumor tissues, leading to a worse immunotherapy response.
FRONTIERS IN MOLECULAR BIOSCIENCES
(2022)